<DOC>
	<DOC>NCT02683655</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy and safety of apatinib in Metastatic Esophageal Cancer.</brief_summary>
	<brief_title>Study of Apatinib in Metastatic Esophageal Cancer</brief_title>
	<detailed_description>Eligible patients will receive apatinib treatment until disease progression or intolerable toxicity or patients withdrawal of consent after the failure of chemotherapy or radiotherapy.</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>1. Age: 18 to75 years old; 2. Pathologically diagnosed with metastatic esophageal squamous cell cancer with measurable metastases outside the stomach (measuring ≥ 10mm on spiral CT scan, satisfying the criteria in RECIST 1.1); 3. Failed in firstline chemotherapy or radiotherapy treatment; 4. ECOG PS of 01; 5. An expected survival of ≥ 3 months; 6. No treated by molecularly targeted therapy. If have received chemotherapy, radiotherapy or surgery, must ≥4 weeks, and adverse reactions or wound has been completely restored; 7. Major organ function has to meet the following criteria: ANC ≥ 1.5 × 109 / L; HB ≥ 90g / L; PLT ≥ 100 × 109 / L; ALB≥30g / L; TBIL≤1.5 times the upper limit of normal (ULN); ALT and AST＜2 × ULN; Plasma Cr＜1.5 × ULN 8. Patient has to voluntarily join the study and sign the Informed Consent Form for the study; 9. Researchers believe that patients can benefit; 1. Pts with other malignant tumor at the same time or in the past. 2. Pregnant or lactating women; 3. Subjects with poorcontrolled arterial hypertension (systolic blood pressure＞150 mmHg and diastolic blood pressure＞100 mm Hg) despite standard medical management; Coronary heart disease greater than ClassII; Echocardiography: LVEF (LVEF)＜50%; 4. Factors that could have an effect on oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction); 5. Subjects with high gastrointestinal bleeding risk, including the following conditions: local active ulcer lesions with positive fecal occult blood test (++); history of black stool, or vomiting blood in the past 6 months; 6. Associated with CNS (central nervous system) metastases; 7. Abnormal Coagulation, with tendency of bleed; 8. With psychotropic drug abuse history and can't get rid of or mental disorder patients; 9. Anastomotic recurrence; 10. Participated in other clinical trials within 4 weeks; 11. Any other condition that might place the patient at undue risk or preclude a patient from completing the study; 12. Other conditions regimented at investigators' discretion.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>